Multiple studies have demonstrated an increased prevalence of t-CH among cancer survivors, with a substantial proportion exhibiting somatic mutations in tumor protein p53 (TP53) and protein phosphatase Mg2+/Mn2+-dependent 1D (PPM1D) genes, both of which are vital components of the DNA damage response (DDR) pathway[63–65]. Here, TP53 is linked to cancer.